BAM
NVCR icon

Belpointe Asset Management’s NovoCure NVCR Stock Holding History

Belpointe Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,340
Closed -$80.6K – 2398
2023
Q1 		$80.6K Sell
1,340
-218
-14% -$17.4K ﹤0.01% 1437
2022
Q4 		$114K Sell
1,558
-40
-3% -$3.01K 0.01% 1168
2022
Q3 		$121K Sell
1,598
-450
-22% -$35.1K 0.01% 1060
2022
Q2 		$142K Buy
2,048
+126
+7% +$9.49K 0.01% 962
2022
Q1 		$159K Sell
1,922
-49
-2% -$3.61K 0.01% 1008
2021
Q4 		$148K Buy
+1,971
New +$198K 0.01% 1021

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Belpointe Asset Management's NVCR Position: Q2 2023 in Review

Belpointe Asset Management sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 1,340 shares — an estimated $80.6K sold.

Belpointe Asset Management first reported a position in NVCR in Q4 2021 and held it in 6 quarters. The position peaked at $159K in Q1 2022. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

  • Belpointe Asset Management reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,340 NovoCure shares in Q2 2023, an estimated $80.6K.
  • Belpointe Asset Management first reported a position in NovoCure in Q4 2021 and held it in 6 quarters.
  • Belpointe Asset Management's NovoCure position peaked at $159K in Q1 2022.
  • 267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.